propafenone has been researched along with Kidney Failure, Chronic in 5 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 6.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "Propafenone is a class Ic agent for the treatment of atrial arrhythmias with a main hepatic metabolism." | 2.68 | Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. ( Di Benedetto, A; Di Ieso, N; Liguori, A; Napoli, C; Sorice, P, 1997) |
| "In sera from patients with chronic renal failure the increase in propafenone binding ratio or the decrease in unbound fraction was associated with the increase in alpha 1-acid glycoprotein concentrations, and there was a correlation (r = 0." | 1.28 | In vitro protein binding of propafenone in normal and uraemic human sera. ( Axelson, JE; Chan, GL; Kerr, CR; McErlane, KM; Price, JD, 1989) |
| "Propafenone kinetics were studied after intravenous and oral dosing in a patient with end-stage renal disease." | 1.28 | Hemodialysis removal of propafenone. ( Burgess, ED; Duff, HJ, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Napoli, C | 1 |
| Sorice, P | 1 |
| Di Benedetto, A | 1 |
| Di Ieso, N | 1 |
| Liguori, A | 1 |
| Poirier, JM | 1 |
| Joannides, R | 1 |
| Geffroy-Josse, S | 1 |
| Fillastre, JP | 1 |
| Etienne, I | 1 |
| Burgess, E | 1 |
| Duff, H | 1 |
| Wilkes, P | 1 |
| Chan, GL | 1 |
| Axelson, JE | 1 |
| Price, JD | 1 |
| McErlane, KM | 1 |
| Kerr, CR | 1 |
| Burgess, ED | 1 |
| Duff, HJ | 1 |
1 trial available for propafenone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Urea Nitrogen; Female; Humans; Injections, Intrav | 1997 |
4 other studies available for propafenone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Propafenone pharmacokinetics in uremic patients treated by peritoneal dialysis.
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysi | 1992 |
Propafenone disposition in renal insufficiency and renal failure.
Topics: Adult; Female; Half-Life; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Propafenone | 1989 |
In vitro protein binding of propafenone in normal and uraemic human sera.
Topics: Adult; Blood Proteins; Dialysis; Humans; Kidney Failure, Chronic; Male; Orosomucoid; Propafenone; Pr | 1989 |
Hemodialysis removal of propafenone.
Topics: Administration, Oral; Biological Availability; Female; Humans; Infusions, Intravenous; Kidney Failur | 1989 |